Research
Sector Report

Q1 2020: A dose of hope for the COVID-19 vaccine — but what next?

  • Multi Asset
  • Healthcare
  • Global

It's a race against time to establish a successful vaccine for COVID-19. Although impressive progress has already been made, there is still a long way to go. Third Bridge Forum spoke to several industry experts in Q1 2020 about some of the approaches being taken with a Coronavirus vaccine for humans and what the main challenges are.

The race is on to find a vaccine for COVID-19, with trials beginning around the world at a seemingly exponential rate. Last week, the UK’s Health Secretary revealed that the University of Oxford would be trialling a vaccine on humans in a matter of days. Pfizer and BioNTech also got the green light for Germany’s first human trials. There are also five candidates at the clinical vaccination stage and 71 in preclinical evaluation, according to a list compiled by the World Health Organisation.4https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf Although four companies represent about 85% of the global vaccine market — GlaxoSmithKline, Sanofi, Merck and Pfizer5https://www.cnbc.com/2020/02/21/coronavirus-brings-light-to-the-35-billion-vaccine-market.html — both legacy players and start-ups have entered the fray.6https://www.marketwatch.com/story/these-nine-companies-are-working-on-coronavirus-treatments-or-vaccines-heres-where-things-stand-2020-03-06 While some projects are focusing on traditional vaccine approaches, others are using newer technology. 

Read More

Submit your email address for full access to our Research content.